- Conditions
- Hypercholesterolemia
- Interventions
- colesevelam HCl tablets, and atorvastatin tablets, colesevelam HCl placebo tablets and atorvastatin tablets
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 13
- States / cities
- Los Angeles, California • Castle Rock, Colorado • Jacksonville, Florida + 10 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2161–2184
of 8,626
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Common Bile Duct Stricture
- Interventions
- Fully covered Metallic Stent, Plastic Stent
- Device
- Lead sponsor
- Medical University of South Carolina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 7
- States / cities
- Chicago, Illinois • Indianapolis, Indiana • Ann Arbor, Michigan + 4 more
- Conditions
- Acute Myeloid Leukemia, AML
- Interventions
- XL999
- Drug
- Lead sponsor
- Symphony Evolution, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 7
- States / cities
- Alhambra, California • Los Angeles, California • Northridge, California + 3 more
- Conditions
- Hypercholesterolemia, Familial Hypercholesterolemia
- Interventions
- Enlicitide Decanoate, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2,912 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 49
- States / cities
- Daphne, Alabama • Foley, Alabama • Phoenix, Arizona + 45 more
- Conditions
- HIV Infections
- Interventions
- Didanosine
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 660 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 66
- States / cities
- Los Angeles, California • Palo Alto, California • San Diego, California + 42 more
- Conditions
- Nephrectomy
- Interventions
- Transverses Abdominis Plane (TAP) block, Quadratus Lumborum (QL) block, Surgeon Infiltration using Exparel
- Procedure
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Coronary Artery Disease
- Interventions
- Lumason
- Drug
- Lead sponsor
- Bracco Diagnostics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 10
- States / cities
- Tucson, Arizona • La Jolla, California • West Hills, California + 7 more
- Conditions
- Cancer Screening Tests
- Interventions
- Decision aid without personalized message, Decision aid with personalized message, Provider notification without personalized message, Provider notification with personalized message
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 50 Years to 75 Years
- Enrollment
- 1,111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana
- Conditions
- Constipation-Predominant Irritable Bowel Syndrome
- Interventions
- Renzapride
- Drug
- Lead sponsor
- Alizyme
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 939 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 126
- States / cities
- Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more
- Conditions
- Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
- Interventions
- Not listed
- Lead sponsor
- Target PharmaSolutions, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 15,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2050
- U.S. locations
- 54
- States / cities
- Scottsdale, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 48 more
- Conditions
- Urothelial Carcinoma, Bladder Cancer
- Interventions
- Pembrolizumab, Gemcitabine, Cisplatin, Consolidative Surgery
- Drug · Procedure
- Lead sponsor
- Jason R. Brown
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2024
- U.S. locations
- 9
- States / cities
- Indianapolis, Indiana • St Louis, Missouri • Albuquerque, New Mexico + 3 more
- Conditions
- Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Mucinous Adenocarcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinofibroma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Carcinoma
- Interventions
- Bevacizumab, Carboplatin, Docetaxel, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis, Paclitaxel, Quality-of-Life Assessment
- Biological · Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 1,052 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2028
- U.S. locations
- 680
- States / cities
- Anchorage, Alaska • Hot Springs, Arkansas • Auburn, California + 421 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Oral semaglutide, Placebo (semaglutide)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- 10 Years to 18 Years
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • New Haven, Connecticut + 18 more
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- alemtuzumab
- Biological
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 69
- States / cities
- Cullman, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 60 more
- Conditions
- Acute Coronary Syndrome
- Interventions
- Ticagrelor, Clopidogrel
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 18,624 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 139
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 136 more
- Conditions
- Hypertension, Coronary Artery Disease
- Interventions
- Nebivolol, Carvedilol
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2008
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Peoria, Arizona • Buena Park, California + 30 more
- Conditions
- Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature
- Interventions
- Not listed
- Lead sponsor
- NICHD Neonatal Research Network
- Network
- Eligibility
- Up to 24 Hours
- Enrollment
- 1,660 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 1994 – 1995
- U.S. locations
- 13
- States / cities
- Palo Alto, California • New Haven, Connecticut • Washington D.C., District of Columbia + 10 more
- Conditions
- Prostate Cancer
- Interventions
- rhPSMA-7.3 (18F) Injection, Positron Emission Tomography scan
- Drug · Diagnostic Test
- Lead sponsor
- Blue Earth Diagnostics
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 356 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Los Angeles, California • Orange, California + 24 more
- Conditions
- Clostridium Infections, Diarrhea
- Interventions
- PAR-101/OPT-80, Vancomycin
- Drug
- Lead sponsor
- Optimer Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 535 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 53
- States / cities
- Gadsden, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 50 more
- Conditions
- HIV Infections
- Interventions
- Stavudine, Zidovudine
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 13 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1994
- U.S. locations
- 44
- States / cities
- Tucson, Arizona • Berkeley, California • Los Angeles, California + 31 more
- Conditions
- Stable Coronary Artery Disease
- Interventions
- Selatogrel, Placebo
- Drug
- Lead sponsor
- Viatris Innovation GmbH
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 346 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 7
- States / cities
- Jacksonville, Florida • Tampa, Florida • Chicago, Illinois + 4 more
- Conditions
- HER-2 Positive Breast Cancer, Metastatic Malignant Neoplasm to Brain
- Interventions
- Tesevatinib, Trastuzumab
- Drug
- Lead sponsor
- Kadmon Corporation, LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 6
- States / cities
- La Jolla, California • Indianapolis, Indiana • Boston, Massachusetts + 3 more
- Conditions
- Adenocarcinoma, Neoplasms
- Interventions
- Torisel
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2012
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 8 more
- Conditions
- Physical Activity
- Interventions
- Virtual Reality games
- Behavioral
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 18 Years to 30 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana